^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    06/19/2015
    Excerpt:
    OPDIVO as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of...adult patients with classical Hodgkin lymphoma that has relapsed or progressed after...autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or...3 or more lines of systemic therapy that includes autologous HSCT.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/16/2022
    Excerpt:
    Hodgkin Lymphoma (Age ≥18 years)...Relapsed/Refractory Disease...CHL...ICE + nivolumab
    Secondary therapy:
    ICE
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pediatric Hodgkin Lymphoma: Subsequent Therapy Options...Nivolumab